SEATTLE, May 16 /PRNewswire-FirstCall/ --
Immunex Corporation (Nasdaq: IMNX) announced today that its shareholders have
voted to approve the merger agreement between Immunex and
Amgen Inc. (Nasdaq: AMGN), the largest biotechnology company in the world.
The closing of the merger remains subject to the approval of the Federal Trade
Commission and other customary closing conditions.
An overwhelming majority of the outstanding shares of Immunex common
stock, were cast in favor of the proposed merger. As is customary, a
certification of the votes will be conducted and is expected to be complete
next week.
Stockholders of Amgen earlier today approved the issuance of shares of
Amgen common stock required to complete the merger.
"We are very pleased with today's shareholder approval of our merger with
Amgen," said Ed Fritzky, Immunex chairman and chief executive officer. "The
strategic vision of the combined companies will expand future patient benefits
by harnessing the significant resources, talents and assets of our companies."
The company expects the merger to be completed in the second half of 2002
and could be completed as early as June 2002, although the exact timing cannot
be predicted with certainty.
Immunex Corporation is a leading biopharmaceutical company dedicated to
improving lives through immune system science innovations.
Note: Except for the historical information contained herein, this news
release contains forward-looking statements that involve substantial risks and
uncertainties. Among the factors that could cause actual results or timelines
to differ materially are risks associated with research and clinical
development, regulatory approvals, our supply capabilities and reliance on
third-party manufacturers, product commercialization, competition, litigation
and other risk factors listed from time to time in reports filed by Immunex
with the Securities and Exchange Commission, including but not limited to
risks described under the caption "Important Factors That May Affect Our
Business, Our Results of Operation and Our Stock Price" within our most
recently filed Form 10-Q. The forward-looking statements contained in this
news release represent our judgment as of the date of this release. Immunex
undertakes no obligation to publicly update any forward-looking statements.
An electronic version of this news release-as well as additional information
about Immunex of interest to investors, customer, future employees and
patients-is available on the Immunex home page at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/434644.html
CONTACT:
media, Robin Shapiro, +1-206-389-4040, or
investors, Mark Leahy, +1-206-389-4363, both of Immunex
Corporation
|
